Polysaccharide storage myopathy (PSSM) is a widely described cause of exertional rhabdomyolysis in horses. Mitochondria play a central role in cellular energetics and are involved in human glycogen storage diseases but their role has been overlooked in equine PSSM. We hypothesized that the mitochondrial function is impaired in the myofibers of PSSM-affected horses. Nine horses with a history of recurrent exercise-associated rhabdomyolysis were tested for the glycogen synthase 1 gene (GYS1) mutation: 5 were tested positive (PSSM group) and 4 were tested negative (horses suffering from rhabdomyolysis of unknown origin, RUO group). Microbiopsies were collected from the gluteus medius (gm) and triceps brachii (tb) muscles of PSSM, RUO and healthy controls (HC) horses and used for histological analysis and for assessment of oxidative phosphorylation (OXPHOS) using high-resolution respirometry. The modification of mitochondrial respiration between HC, PSSM and RUO horses varied according to the muscle and to substrates feeding OXPHOS. In particular, compared to HC horses, the gm muscle of PSSM horses showed decreased OXPHOS-and electron transfer (ET)-capacities in presence of glutamate&malate&succinate. RUO horses showed a higher OXPHOS-capacity (with glutamate&malate) and ET-capacity (with glutamate&malate&succinate) in both muscles in comparison to the PSSM group. When expressed as ratios, our results highlighted a higher contribution of the NADH pathway (feeding electrons into Complex I) to maximal OXPHOS or ET-capacity in both rhabdomyolysis groups compared to the HC. Specific modifications in mitochondrial function might contribute to the pathogenesis of PSSM and of other types of exertional rhabdomyolyses.
Introduction
Muscular disorders represent a common cause of disability and of poor athletic performance in horses (Aleman 2008; Martin et al. 2000) . Among them, polysaccharide storage myopathy (PSSM) is widely recognized as a cause of recurrent episodes of muscle disease. Clinical symptoms and results of traditional complementary exams such as muscle enzymes measurement and urinalysis are generally not very useful for the specific diagnosis of PSSM, while muscle biopsy is considered an essential tool for this purpose. Characteristic features of PSSM on histological examination are the presence of abnormal accumulations of glycogen under the cell membrane of myofibers or in the cytoplasma. This glycogen is typically stained (Bpositive^) by the periodicacid Schiff (PAS) staining and it can be resistant or sensitive to enzymatic digestion with amylase (Valberg et al. 1992; McCue et al. 2006) . In 2008, a major advance was made with the discovery of a dominant gain-of-function mutation in the glycogen synthase 1 gene (GYS1) coding for glycogen synthase (GS) enzyme (McCue et al. 2008a, b) . This mutation is associated to a conformational change perturbing the GS activity in skeletal muscle, rendering the enzyme constitutively active (Maile et al. 2017) , thus leading to abnormal polysaccharide inclusions in myofibers (McCue et al. 2008a, b; Stanley et al. 2009 ). The discovery of the mutation in the (GYS1 gene coding for the GS enzyme allowed the development of a sensitive and specific genetic test. Based on the genetic testing, PSSM mutation has been observed histologically in 16% of horses with amylase-sensitive polysaccharides and in 70% in horses with amylase-resistant polysaccharides (McCue et al. 2008a ). Indeed, it has been suggested that two forms of PSSM exist, even if they share the same histological features: a type-I PSSM, positive to GYS1 mutation and a type-II PSSM, lacking GYS1 mutation Stanley et al. 2009 ). Besides recent evidence of a genetic mutation at the origin of this glycogenosis, the whole metabolic puzzle underlying the PSSM phenotype is still incomplete. Impaired energy transformation in PSSMaffected muscles and reduced maximal oxygen consumption per body mass (V O2max ) in these horses, in comparison to healthy controls, have been documented (Valberg et al. 1995; Annandale et al. 2005 ). This energetic imbalance was originally thought to result from a limitation in glycolysis and not from a limitation in oxygen transport (Valberg et al. 1995) . In contrast to human glycogen storage diseases (GSD), however, PSSM-affected horses showed no deficiencies in glycolytic or glycogenolytic enzymes (Valberg et al. 1998) . It has been reported that muscles of affected horses show no change in post-exercise levels of pyruvate and ATP, but measures were realized on whole muscle homogenates and not on individual fibers (Annandale et al. 2005; Borgia et al. 2010) . These researches have suggested that PSSM muscle could be energetically compromised, but the precise site of dysfunction is still unclear. Studies of individual muscle fibers in animals affected by metabolic myopathies have been advocated so as to better localize the metabolic failure (Annandale et al. 2005; Borgia et al. 2010; Valberg et al. 1998) .
Mitochondria play a crucial role in eukaryotic cellular metabolism, producing ATP through the oxidative phosphorylation (OXPHOS) process. In human medicine, impairment of mitochondrial activity has been underlined as a key factor in a variety of neurodegenerative and metabolic diseases, cardiomyopathies and cancer (Nunnari and Suomalainen 2012) . Of particular interest, some human GSD have also revealed features of mitochondrial dysfunction suggesting its likely contribution to exercise-related symptoms. These abnormalities have been observed in both mitochondrial morphology and bioactivity; specific causes and features of mitochondrial impairment vary depending on the specific GSD type (De Stefano et al. 1996; Selak et al. 2000; Kurbatova et al. 2014; Lim et al. 2015; Melis et al. 2016; Rossi et al. 2018) . Concerning specifically equine PSSM, in one study (Barrey et al. 2009 ) a down-regulation of many genes involved in mitochondrial activity as well as signs of mitochondrial degeneration have been observed in horses affected by type-I PSSM. More precisely, this down-regulation involved most of the mitochondrial tRNA, genes coding for the respiratory chain sub-units (ND2, ND3, ND5, ND6, COX2 and COX3), nuclear genes involved in the aerobic metabolism of mitochondria (GNAS, SLC2a2, ATP5L, ATP5J, ATP5D and ATP5H), glucose transporter GLUT2 and mitochondrial carrier ornithine transporter (SLC25A15). An up-regulation of pro-inflammatory genes (as IL-18 among others) was observed, thus indicating chronic muscle inflammation. Moreover, ultrastructural changes were also detected in mitochondria and muscle fibers: decreased cristae number, mitochondrial swelling, formation of myelinic bodies and severe mitochondrial and myofibrillar loss due to abnormal glycogen accumulation. A down-regulation of VEGFα, involved in capillarization and oxygen distribution of regenerated muscle fibers was also observed.
Up to now, specific functional assessment of mitochondrial respiration in muscles of PSSM-affected horses has not been performed. This study uses high resolution respirometry (HRR), an advanced diagnostic tool already employed to detect mitochondrial dysfunctions in human (Sperl et al. 1997; Gehrig et al. 2016 ) and horse diseases (Votion et al. 2010; Votion et al. 2012; Houben et al. 2015) . The aim is to determine the functional changes in muscle of horses suffering from PSSM horses by comparing them with healthy controls (HC) and with horses suffering from exertional rhabdomyolysis of unknown origin (RUO). We hypothesized that the mitochondrial function is impaired in PSSM-affected horses. On the basis of what is described in literature, we expected to find a decreased mitochondrial respiration in horses affected by PSSM when compared to healthy horses.
Materials and methods

Horses and complementary exams
Nine horses of different breeds (2 French Saddle, 1 Paint Horse, 2 light draft horses, 1 Quarter Horse, 1 Belgian Warmblood, 1 Holstein, and 1 crossbred horse, mean age 9.1 ± 5.1 years old, mean weight 537 ± 76.1 kg) were referred between October 2011 and October 2014 to the Faculty of Veterinary Medicine at the University of Liège with a history of exercise-induced recurrent rhabdomyolysis. Inclusion criteria for the study were the presence of one or more of clinical symptoms as exercise intolerance, stiffness, sweating, muscle trembling, reluctance to move and gait abnormalities and when possible a blood sample collected within 24 h after the beginning of symptoms revealing an abnormal increase of serum creatinine kinase (CK) activity (Aleman 2008 ). In our study in 8 cases out of 9 a blood sample had been done by the treating veterinarian. Eight horses out of 9 were referred for a poor performance and/or suspicion of rhabdomyolysis, several days or even weeks after the last episode of myopathy. One horse (horse 9) was referred for acute rhabdomyolysis in an emergency setting. A complete clinical examination was performed so as to exclude other potential non-muscular pathologies. Blood was collected by jugular venipuncture for hematological and biochemical analyses and to measure vitamin E and blood electrolytes, as vitamin E deficits as well as abnormal electrolyte clearances can predispose to recurrent rhabdomyolysis. Urine was collected to detect pigmenturia (using commercial urine dipstick tests Krulab, Kruuse, Denmark) and to perform a fractional electrolyte excretion test so as to evaluate horses' electrolyte balance (for Na Hoven et al. 1985) . Moreover, gm muscle is one of the primarily and most severely affected muscles in cases of PSSM (Valentine 2003) . If the horse was considered clinically sound the day of the consultation, a 12-min exercise test of moderate intensity (trot and canter) on the high-speed treadmill or on a lunge line was performed in order to measure post-exercise CK, 4 h after the end of exercise. Owners gave their consent to use muscle biopsies of their horses for HRR and to use clinical data for this study.
Muscle tissue sampling
Biopsy sampling procedure was approved by the Animal Ethic Commission of the University of Liege (agreement number 07-629). An average of 20 mg of muscle tissue was collected at a 50 mm depth from the tb and gm muscles using a 14 G biopsy needle mounted on an automatic instrument (ProMag™ Ultra Biopsy Instrument, Angiotech, Gainesville, Fl, USA). The sampling site was shaved (1 cm 2 ). Skin was desensitized with 0.5 ml of mepivacaine (Scandicaine ® 2%, AstraZeneca, Brussels, Belgium), strictly injected under the skin not to interfere with muscle mitochondrial energetics (Nouette-Gaulaina et al. 2011) . The zone was aseptically prepared with povidone iodine and alcohol. After a skin incision with a scalpel blade n. 11, muscle samples were taken in the long head of the tb muscle determined as the intersection between a vertical line raised from the tricipital line and a line running from the point of the shoulder to the elbow, as previously described (Votion et al. 2010; Votion et al. 2012) . Biopsy on the gm muscle was performed one-third the distance along a line running from the tuber coxae to the root of the tail (Lindholm and Piehl 1974) . The small skin incision was not closed but only disinfected after the procedure. Biopsies were well tolerated and sedation was not required apart from one particularly reactive horse that received dose of 0.01 mg/kg of detomidine (Domidine ® , Eurovet Animal Health, Belgium).
Muscle samples were immediately transferred into 10 ml of ice-cold relaxing solution BIOPS, a special solution for preservation of muscle biopsy for the assessment of mitochondrial function (Letellier et al. 1992; Veksler et al. 1987) , or into buffered 10% formalin for histological analysis. Fibers were transported on ice to the laboratory, then stored at 4°C until further preparation and analyzed within 24 h from sampling.
Permeabilized muscle fiber preparation
Muscle samples kept into ice-cold BIOPS were separated mechanically using two pairs of forceps and connective tissue was removed. Permeabilization of plasma membrane was ensured by agitation during 30 min at 4°C in 2 ml of BIOPS solution containing 50 μg/ml saponin. Fiber bundles were rinsed by gentle agitation for 10 min in ice-cold mitochondrial respiration medium MiR05 (Gnaiger et al. 2000) . Permeabilized muscle fibers were immediately used for HRR.
High-resolution respirometry
Two to 3 mg wet weight (W w ; microbalance; Mettler Toledo, Zaventem, Belgium) of permeabilized muscle fibers were added to respiration chambers (Oroboros Oxygraph-2 k, Innsbruck, Austria) containing 2 ml of MiR05 at 37.0°C. Mitochondrial OXPHOS-and electron transfer (ET)-capacities were determined in permeabilized fibers using two substrate-uncoupler-inhibitor-titration (SUIT 1 and SUIT 2) protocols as previously described (Pesta and Gnaiger 2012; Votion et al. 2012 ). These two protocols differed basically by the first substrates added to chambers to initiate the mitochondrial respiration. In SUIT 1, glutamate&malate (GM; 10 and 2 mM) were first added, while in SUIT 2 pyruvate&malate (PM; 5 and 2 mM) were initially used. When adding ADP (2.5 mM) in presence of these NADH-linked substrates (N), electrons flow through Complex I (N-OXPHOS capacity: GM and PM in SUIT 1 and SUIT 2, respectively). Whereas both SUIT 1 and 2 measure the capacity of Complex I, they involve different dehydrogenase and transporters. N-OXPHOS capacity relates on glutamate dehydrogenase for SUIT 1 and on pyruvate dehydrogenase complex (PDC) and pyruvate transporter for SUIT 2. Then, it was checked that the measured oxygen consumption remained at the same level after addition of cytochrome c to ensure that the preservation or permeabilization procedures had not damaged the outer mitochondrial membrane. In SUIT 2, OXPHOS was subsequently stimulated by addition of another NADH-linked substrate, i.e. glutamate (G; 10 mM) thus obtaining N-OXPHOS capacity with PMG. The following steps were common to both SUIT protocols. The addition of succinate (S; 10 mM), a FADH 2 -linked substrate, allowed the measurement of OXPHOS when electron transfer in the NADH-and succinate pathways (NS pathway) converged at the Q-junction (NS pathway OXPHOScapacity): GMS and PMGS in SUIT 1 and 2, respectively. At this step, the ETS is coupled to the phosphorylation system and proton pumps generate an electrochemical potential that drives phosphorylation of ADP to ATP (coupled flow). A stepwise addition of protonophore, FCCP (0.05 μM followed by 0.025 μM steps until reaching maximal oxygen flux), was then performed to uncouple the ETS from ATP synthesis to measure the capacity of the ET (NS pathway ET-capacity; GMS in SUIT 1 and PMGS in SUIT 2). The NS pathway ET-capacity is not limited by the substrate or the phosphorylation system and thus, gives an estimate of maximal capacity for electron transfer. Then rotenone (Rot; 0.5 μM) was added to inhibit Complex I so as to obtain S-sustained respiration alone (S pathway ET-capacity). Finally, antimycin A (Ama; 2.4 μM) was added to block the ETS at Complex III thus obtaining residual oxygen consumption (ROX) due to oxidative side reactions. Oxygen concentration (μM) and oxygen fluxes per muscle mass (pmol O 2 ·sˉ·mgˉ1 W w ) were recorded and analyzed using Datlab software (Oroboros Instruments, Innsbruck, Austria). During the SUIT protocols, oxygen levels were maintained above air saturation (between 200 and 500 μM O 2 ) to avoid experimental oxygen limitation (Gnaiger 2014) . Oxygen fluxes were corrected for the flux of oxygen due to instrumental background and for ROX.
Steady-state oxygen fluxes were expressed as flux control ratios, FCR, with internal normalization for ET-capacity with convergent electron input into the NADH and succinate pathways (NS pathway OXPHOS-capacity). The FCR give punctual information about coupling and substrate control independent of mitochondria content of tissue. Substrate control ratios (SCR) were also calculated in each SUIT protocol; while FCR are calculated at a constant substrate state, SCR are flux ratios at constant coupling state (LEAK, OXPHOS, ET). The phosphorylation system control ratio (OXPHOS/ET) was also calculated as it represents an expression of the gap existing between OXPHOS and ET-capacity (Votion et al. 2012) . Respirometric measurements of each specimen were performed in duplicate for each protocol. Data were compared with values previously obtained from healthy, fit horses (HC), but not in competitive training. Ten horses were used as HC for SUIT 2 and 8 were available for SUIT 1, with 2 to 4 measurements for each horse. Unfortunately, we had no available data for the gm muscle of HC in SUIT 2.
Muscle histopathology
Muscle biopsies fixed in 10% buffered formalin were trimmed and then embedded in paraffin wax according to standard laboratory methods. Tissue sections of 5 μm were stained with hematoxylin and eosin (HE), PAS, amylase-PAS, and then examined by light microscopy. The HE stains were used for evaluating the presence of pathological changes such as: fiber swelling, Zencker degeneration/necrosis, internalized nuclei, atrophy and subsarcolemmal or intracytoplasmic vacuoles. For the amylase-PAS stain, sections were digested with α-amylase following the protocol furnished by the producer (Sigma-Aldrich Steinheim, Germany, procedure n°395).
Genotyping
Genotyp in g wa s performed a t th e Compa rative Neuromuscular Diseases Laboratory of the Royal Veterinary College in London. A DNA sample from EDTA blood was tested for GYS1 mutation (R309H) associated to type-I polysaccharide storage myopathy (McCue et al. 2008a, b) 
. Horses were identified as homozygous (H/H), heterozygous (H/R) or normal (R/R).
Statistical analysis
A general linear mixed model (SAS, Cary, NC, USA) was used for data analysis. The response variables were the respirometric parameters, while the predictive variables (fixed effects) were the muscle sampled and the group of animals (HC, PSSM or RUO) as well as the interaction between the two. Horse was considered a random effect. In this multifactorial design results were reported as least square means and significance was set at p < 0.05.
Results
Genotype confirmation of the pathology
Five horses out of nine (cases 1, 2, 3, 4, 7) were diagnosed affected by type-I PSSM because tested positive for the GYS1 mutation (R309H). These five horses were all heterozygous (R/H). Horses were then divided in two groups depending on results of the genetic test, and classified as type-I PSSM group (i.e. with a positive genetic test) or as horses suffering from RUO (negative to the genetic test).
Clinical examination, blood and urine tests
Hematology and electrolyte status were normal in all horses apart from horse 9 that showed a neutrophilic leukocytosis, mild hypocalcaemia and hyperphosphatemia. Serum CK and AST concentrations measured at rest were outside reference ranges in 6/9 and in 7/9 horses, respectively. Vitamin E status was lower than normal limits (<2 mg/l) in 2/9 horses. Pigmenturia was present in horse 9 only and fractional electrolyte excretion was normal in all cases apart from horse 9 where the analysis was not performed due to isotonic fluid therapy that had been administered at home by the treating veterinarian before referral. Detailed results of biochemical analyses are summarized in Table 2 .
Effort test
The 12-min effort test of moderate intensity (walk, trot and canter either on a lung line or on the treadmill) was well tolerated by each horse without triggering an episode of rhabdomyolysis. Horse 1 showed a significant increase in serum CK concentration after exercise (more than two folds the rest value). Only horse 9 did not perform an exercise test because still painful at the moment of examination.
Muscle histopathology
In six horses (cases 1, 2, 3, 4, 6, 7, 9), muscle histopathology revealed non-specific, degenerative lesions mainly consisting in swollen, rounded and asymmetric fibers, internal nuclei and rimmed cytoplasmic vacuoles (Fig. 1) . The extent and the degree of the degenerative process varied between cases and muscles but without any apparent correlation with age, severity of clinical signs or activity of muscles enzymes. Two horses (case 5 and 8) had very mild histological lesion that were not considered significant. Abnormal subsarcolemmal and cytoplasmic glycogen was PAS-positive in all confirmed type-I PSSM horses and amylase-sensible in all cases except for case 7 where it was resistant to amylase digestion. Figure 2 shows respiration in tb and gm muscles in type-I PSSM, RUO and HC groups. Within each group, no significant differences were observed between tb and gm muscles for all measured parameters except for succinate pathway capacity in the type-I PSSM group that was significantly lower in the gm than in tb muscle in both protocols (p = 0.005 for SUIT 1 and p = 0.038 for SUIT 2).
Mitochondrial function
Polysaccharide storage myopathy horses versus healthy controls
The tb (Fig. 2a) and gm muscles (Fig. 2b) were compared between HC, RUO and PSSM for respiratory capacity expressed as flux per mass of tissue. The differences between the HC and the PSSM groups in SUIT1 were muscle specific. In PSSM horses compared to controls, the tb muscle (Fig. 2a) showed a reduced NS pathway ET-capacity (PMGS; p = 0.019), whereas the gm muscle (Fig. 2b) showed reduced NS-OXPHOS capacity (GMS; p = 0.01) and reduced S pathway ET-capacity (p = 0.02). Furthermore, in the gm muscle, the difference in NS pathway ET-capacity (GMS) between PSSM and HC approached significance (p = 0.065).
The respirometry data were expressed as FCR over maximal ET-capacity (Fig. 3 and Table 3 ). In the tb muscle, FCR differed significantly between HC and PSSM horses (Fig. 3) . Generally speaking, all the FCR changes indicated a greater contribution of NADH pathway to maximal ET-capacity (NS pathway ET-capacity) in PSSM horses compared to HC. In the gm muscle, the FCR did not show any significant differences between HC and PSSM horses (Table 3) . Both muscle showed changes in the SCR (Fig. 4) . When compared to HC, PSSM horses showed a greater contribution of NADH pathway (Complex-I linked substrates) to both maximal OXPHOScapacity and S pathway ET-capacity.
Observations in horses suffering from exertional rhabdomyolysis of unknown origin
In the gm muscle, all fluxes in SUIT 1 protocol were significantly higher in the RUO group compared to the PSSM group (Fig. 2b) . In contrast, in the tb muscle, only N pathway OXPHOS-capacity (GM) and NS pathway OXPHOScapacity (GMS) differed significantly between PSSM and RUO horses (p = 0.013 and p = 0.029 respectively). No significant differences were found in SUIT 2 between PSSM and RUO groups in gm or in tb muscle biopsies.
The only significant changes observed in FCR and SCR parameters in RUO versus PSSM horses concerned the tb muscle with a lower relative contribution in the RUO group of succinate pathway to NS pathway ET-capacity in SUIT 1 (p = 0.041). A similar difference was measured in SUIT1 between RUO horses and HC, a lower contribution of succinate pathway to NS pathway ET-capacity (p = 0.006) and to maximal OXPHOS-capacity (p = 0.046) in RUO horses.
The N pathway OXPHOS-capacity in the presence of glutamate&malate was significantly higher in RUO horses compared to HC for both muscles (p = 0.0005 and p = 0.046 respectively in tb and gm; Fig. 2) . No other significant difference in fluxes per mass was found between RUO and HC groups. Significant changes in FCR and SCR measures were observed in RUO horses compared to HC in both muscles and with the same trend of PSSM horses (Table 3a , b), these differences concerned mostly SUIT 1. Again, these changes indicated a greater contribution of Complex I to NS pathway OXPHOS-capacity in RUO horses versus HC.
Alterations in individual horse
It has to be noticed that one type-I PSSM horse (horse 7) presented a different tendency in comparison to the other horses of the group. At each step of SUIT 1 and SUIT 2 protocols oxygen fluxes were higher than the other 4 PSSM horses but also higher than HC, while respiratory ratios (FCR and SCR) were not different from other type-I PSSM cases for both SUIT protocols.
Discussion
Mitochondria play a central role in cellular energetic metabolism and mitochondrial damage is associated with a variety of human neurodegenerative disorders. In particular, patterns of mitochondrial dysfunction have been observed in some human GSD such as McArdle disease (GSD V) and Pompe disease (GSD II) (De Stefano et al. 1996; Kurbatova et al. 2014; Lim et al. 2015; Selak et al. 2000; Melis et al. 2016; Rossi et al. 2018) . Equine PSSM represents a common cause of exertional rhabdomyolysis in many equine breeds (Valberg et al. 1992) . Despite the recent discovery of a point mutation of the GYS1 gene as responsible of the glycogen storage trouble in type-I PSSM, the metabolic phenomena behind this pathology have not been totally elucidated. We investigated PSSM-affected equine muscle fibers using an innovative diagnostic tool, the HRR. This tool is aimed at taking an important place in the future as a diagnostic routine in the context of equine muscle disorders, where the complexity of underlying metabolic troubles overcomes the limits imposed by basic ancillary complementary exams.
Results of our study reveal for the first time changes in mitochondrial function in horses diagnosed with type-I PSSM in contrast to both HC and horses affected by RUO. Differences emerged depending on the muscle studied, most probably due to different fibers composition and metabolic properties among muscles (Van den Hoven et al. 1985) . Our study shows that quantitative changes in mitochondrial respiration (i.e. per mg of tissue) are more readily observable in the gm than in the tb but in contrast, the qualitative changes (i.e. modifications in ratios, FCR and SCR) are more prominent in the tb. In a previous study investigating the mitochondrial function of French Standardbred racehorses, it was also found that FCR and SCR calculated from fluxes recorded in tb enabled the discrimination of horses at risk of exertional rhabdomyolysis versus unaffected horses while absolute OXPHOS and ET-capacities were not informative (Houben et al. 2015) . In the aforementioned study involving racehorses, gm muscle was not sampled. Both studies suggest that qualitative changes more efficiently reflect the pathological process. We are aware that the limited number of horses in the PSSM and in the RUO groups represents a not negligible limit in our study. Nonetheless, it has to be taken into account that muscle problems are an important but not a major cause of poor-performance in equine veterinary medicine, and PSSM is only one among other potential muscle disorders. Thus, recruiting PSSM-or RUO-affected horses represented and still represents a challenge. Moreover, the lack of data from the gm muscle of HC in SUIT2 limits the conclusions that can be drawn from our results. Further sampling to obtain data from the gm muscle of sound horses is advocated.
In this study we did not assess the mitochondrial content using a marker as citrate synthase activity, for example. It could be hypothesized that mitochondrial density might be impaired in RUO and PSSM affected horses, thus helping to interpret some of our results. Unfortunately we were limited in our muscle biopsies to about 30 mg of tissue and thus, we were only able to perform SUIT 1 and SUIT2.
Type-I polysaccharide storage myopathy horses versus healthy controls
When comparing PSSM to HC horses, we observed that the most apparent decrease in mitochondrial respiration concerned NS pathway OXPHOS-capacity and S pathway ETcapacity in gm in the absence of pyruvate (SUIT 1), while only NS-ET was decreased in tb in the presence of pyruvate (SUIT 2). It has been demonstrated that PSSM-affected horses have a lower V O2max than healthy animals as well as a lower maximum total power (aerobic and anaerobic) (Valberg et al. 1995) even if not as severe as those measured in a case of an Arabian filly suffering from Complex I deficiency (Valberg et al. 1994) . Thus, the hypothesis that PSSM horses have a dysregulation in the muscle oxidative capacity and in the energy generation pathway has been formulated (Valberg et al. 1995) . Different studies have been conducted so as to identify the key-point of metabolic dysfunction, if it lies upstream or downstream the Embden-Meyerhof pathway. It does not appear in literature that the limitation of OXPHOS is induced by an impaired substrate delivery, as it happens in some human glycogenoses (i.e. phosphofructokinase or myophosphorylase deficit). In different studies PSSM horses did not show significantly different muscle concentrations of pyruvate, G-6-P, lactate or ATP depletion with exercise in comparison to controls (Annandale et al. 2005; Borgia et al. 2011; Valberg et al. 1999 ) but an accumulation of inosine monophosphate (IMP) concentration revealing premature adenine nucleotide degradation (Annandale et al. 2005) , so it has been suggested that the limitation of oxidative metabolism would lie after the a b Fig. 2 Tissue-oxidative phosphorylation capacity (OXPHOS-capacity, coupled) and electron transport system (ET-capacity, noncoupled) capacities obtained by high-resolution respirometry. The number of horses per group is indicated by N and the number of myofiber incubations by n. Two muscles are analyzed, triceps brachii (tb, a) and gluteus medius (gm, b). Three groups are compared: healthy controls (HC, n = 8 in for tb and gm in SUIT 1 and n = 10 only for tb in SUIT 2, N = 8 and 10 horses respectively), horses affected by polysaccharide storage myopathy (PSSM, n = 11 for tb and n = 13 for gm in SUIT 1, n = 10 for tb and n = 14 for gm in SUIT 2, N = 5), and horses affected by rhabdomyolysis of unknown origin (RUO, n = 9 for tb, n = 11 for gm in SUIT 1, n = 10 for tb and n = 11 for gm in SUIT 2, N = 4). Two states (OXPHOS and ET-capacities) and three pathways (N for NADH pathway, S for succinate pathway and NS pahway for NADH and succinate pathway) are included. Substrates employed are GM glutalte&malate (GM), glutamate&malate&succinate (GMS), pyruvate&malate (PM), pyruvate&malate&glutamate (PMG), pyruvate&malate&glutamate&succinate (PMGS), and succinate in presence of rotenone (S (Rot)). Subscript 1 and 2 indicates the data coming from SUIT 1 and 2 respectively. Data in (a) are for the tb muscle and data in (b) are for the gm muscle. Box plots indicate the minimum, 25th percentile, median, 75th percentile, and maximum. Significant differences between groups are identified with * for p values <0.05 and with ** for p values <0.01. Values from HC were not available from our biobank for gm muscle in SUIT 2 b conversion of glycogen to pyruvate (Borgia et al. 2010 ). In our study, an altered mitochondrial activity appeared despite the provision of exogenous energetic substrates. In addition, because there was no change in NADH-OXPHOS-capacity involving the PDH complex (SUIT 2, with pyruvate&malate) our results are not suggestive of a defect at the level of this enzymatic complex or at the pyruvate transporter. Features of mitochondrial dysfunction have already been described in PSSM equine muscles, as demonstrated by the downregulation of many genes involved in mitochondrial activity and by the observation of ultrastructural changes (Barrey et al. 2009 ). Here we used another method to measure the functional changes in mitochondrial OXPHOS PSSM-affected horses. Our results show that despite the provision of energetic substrates, the capacity of some mitochondrial components is modified. As suggested by human and equine literature, many factors can participate to the pathophysiology of the altered mitochondrial function: hypoxia, muscle fibers inflammation, morphological distortion of mitochondria due to glycogen cytoplasmic accumulation and down-regulation of nuclear and mitochondrial genes. The exact link between all these features in the complex metabolic puzzle of equine PSSM has yet to be determined.
It has been suggested that caution must be taken when analyzing mitochondrial activity in muscle storage diseases (by lipids or glycogen) as results can be misinterpreted if not properly normalized (Selak et al. 2000) . The FCR used in the present study represent the steady-state oxygen flux with internal normalization for ET-capacity with convergent electron input into the NADH and succinate pathways (NS pathway ET-capacity). This internal normalization helps distinguishing changes of mitochondrial quality versus mitochondrial density, and it yields higher statistical resolution compared to OXPHOS analysis based on external mitochondrial markers (Nunnari and Suomalainen 2012) . The OXPHOS/ET ratios with NS pathway obtained in both protocols were equal in the three groups of horses studied, indicating no change in limitation on OXPHOS-capacity by the phosphorylation Table 3 Respiratory parameters in the gluteus medius (gm) muscle expressed as flux control ratios (FCR), over the maximal ETcapacity with substrates feeding electrons into the NADH and the succinate pathways simultaneously N and n are defined as for Fig.2 . Three groups are compared: healthy controls (HC, n and N = 8 in SUIT1), horses affected by polysaccharide storage myopathy (PSSM, n = 13 in SUIT1 and n = 14 in SUIT2, N = 5), and horses affected by rhabdomyolysis of unknown origin (RUO, n = 11 in SUIT1 and 2, N = 4). Two states (OXPHOS and ET-capacities) and three pathways (N for NADH pathway, S for succinate pathway and NS for NADH and succinate pathway) are included. Subscript 1 and 2 indicates the data coming from SUIT 1 and 2 respectively. Values are presented as the median (min-max) for each group. Values from HC were not available from our biobank for gm muscle in SUIT2. No significant differences were found between the three groups 0 Fig. 3 Respiratory parameters in the triceps brachii (tb) expressed as flux control ratios (FCR), over the maximal ET-capacity with substrates feeding electrons into the NADH and the succinate pathways simultaneously (NS). N and n are defined as for Fig.2 (Lemieux et al. 2016; Votion et al. 2012 ) and also show a greater contribution of NADH-linked pathway over both NADH and succinate pathways (NS pathway) and succinate pathway (S pathway) in type I-PSSM compared to HC.
Observations in horses suffering from exertional rhabdomyolysis of unknown origin Surprisingly, compared to control and PSSM groups, RUO horses showed a higher N-OXPHOS-capacity in the presence of glutamate&malate (SUIT 1) in both tb and gm muscles. Again, the change was not observed when pyruvate&malate were used as substrate to feed the NADH pathway. This observation could support the hypothesis that RUO horses, but not type-I PSSM, may show specific changes in NADHsustained OXPHOS independent of the PDH complex activity. This specific modification of the NADH pathway also impacted maximal ET-capacity in the presence of glutamate&malate&succinate (NS pathway ET-capacity) and was accompanied with a lower contribution of succinatelinked pathways (S pathway) to maximal OXPHOS and ETcapacity in tb muscle of RUO horses in comparison to the other two groups. Similar to the results in PSSM horses, FCR and SCR also showed a higher contribution of Complex I-linked substrates (NADH pathway) to maximal ET-capacity in RUO when compared to HC. These results suggest that some specific changes at the level of the ET take place in muscle of horses suffering from myopathy, and these changes differ depending on the primary pathology. Furthermore, in horses affected by RUO a final diagnosis was not obtained, so the possibility of an involvement of pathologies linked to type-I PSSM (as PSSM type-II) that could potentially share similar metabolic features (thus rendering differences between type-I PSSM and RUO results less definite) cannot be excluded. Obviously, another important limit of this study is represented by the small number of subjects that could have influenced and reduced the statistical relevance of some results. Furthermore, the use in the future of other energy substrates such as fatty acids could help the differentiation between different types of myopathy.
Observations in individual horse
One mare (case 7) belonging to the type-I PSSM group showed abnormally high oxygen flux levels in comparison to the mean of other PSSM horses and to HC while respiratory ratios were equivalent to those of other PSSM cases. It has to be underlined that this mare was the only one in the PSSM group that was already correctly managed (in nutrition and physical activity, as generally indicated in case of PSSM diagnosis) since months by her owners, after the last episode of muscle pain. Indeed, at the time of consultation, the mare was performing well. It is difficult to discuss these results, but it could be speculated that nutritional and sports measures a b Fig. 4 Respiratory parameters expressed as substrate control ratios (SCR). N and n are defined as for Fig.2 . Two muscles are analyzed, triceps brachii (tb, a) and gluteus medius (gm, b). Three groups are compared: healthy controls (HC), horses affected by polysaccharide storage myopathy (PSSM), and horses affected by rhabdomyolysis of unknown origin (RUO). Substrates employed are GM glutalte&malate (GM), glutamate&malate&succinate (GMS) in SUIT1, pyruvate&malate (PM), pyruvate&malate&glutamate (PMG), pyruvate&malate&glutamate&succinate (PMGS) in SUIT2. Succinate in presence of rotenone (S (Rot)) is common to both protocols. Subscript 1 and 2 indicates the data coming from SUIT1 and 2 respectively. Box plots indicate the minimum, 25th percentile, median, 75th percentile, and maximum. Significant differences between groups are identified with * for p values <0.05 and with ** for p values <0.01. Values from HC were not available from our biobank for gm muscle in SUIT 2 already applied in this case could have contributed to mitochondrial recovery, or that a compensatory up-regulation of mitochondrial number or activity could lay beyond these findings. It is known that mitochondrial genetic disorders in human medicine are generally irreversible apart from few entities (i.e. reversible infantile respiratory chain deficiency) (Boczonadi et al. 2015) but little information exists about the reversibility of mitochondrial dysfunction associated to storage myopathies in humans in response of specific treatments (Nunnari and Suomalainen 2012) . Moreover, type-I PSSM represents a unique animal model of abnormal glycogen metabolism different from human glycogenoses and the recent suggestion of a compromised mitochondrial function in affected horses it is yet to be completely elucidated and linked to the primary GYS1 mutation.
Conclusion
This study suggests that investigation of mitochondrial function using HRR on muscle fibers obtained by non-invasive muscle microbiopsy offers a useful tool for the assessment of mitochondrial dysfunction in horses suffering from muscular disorders. We detected significant bioenergetical impairments in mitochondria of type-I PSSM-affected horses, changes that are likely participating to the genesis of the observed clinical symptoms. Our results also show that some results are specific to one muscle emphasizing the need for sampling both muscles (tb and gm) when investigating equine muscle disorders. HRR is an innovating tool that allows the assessment of mitochondrial function in different pathologies involving an energetic imbalance in human and veterinary medicine, its usefulness in different equine muscle disorders needs to be advocated.
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